EQS-News: Signature of a Memorandum of Understanding with Perfect Holding SA
About Kinarus Kinarus AG is a a privately owned clinical-stage pharmaceutical company formed in Basel, Switzerland, in 2017. Managed by experienced healthcare executives, Kinarus is focused on bringing novel treatments to patients suffering from serious viral, respiratory and ophthalmic diseases. The company's unique and innovative combinatorial therapeutic candidate KIN001 has the potential to transform numerous therapeutic areas such as Covid-19 (currently in phase 2 clinical trials), age-related macular degeneration (wet AMD) and idiopathic pulmonary fibrosis (IPF).
For more information, please visit the company's website at www.kinarus.com.
Contact information:Kinarus AG Alexander Bausch CEO Tel: +41 61 633 email@example.com ?
Perfect Holding SA Tel: +41 21 552 6016 Avenue de Florimont 3 CH-1006 Lausanne www.perfect.aero
Disclaimer This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Kinarus AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.
End of Media Release